Pharmaceutical giant, GlaxoSmithKline, has recalled one of it’s most popular heartburn medications, Zantac, after unacceptable levels of potential carcinogen were reported to be found in the drug.
The heartburn medication, Ranitidine, which is marketed as Zantac, has been recalled globally after the FDA (US Food and Drug Administration) found an impurity that may cause cancer.
As per the Therapeutic Goods Administration website “The TGA is advising consumers and health professionals that several ranitidine-containing products have been removed from the Australian market due to contamination with an impurity called N‑nitrosodimethylamine (NDMA).”
Zantac 300mg Tablets and Zantac 150mg Tablets, Zantac 150mg/10mg Syrpup and Zantac 50mg/2ml Injection have been recalled.
Anyone who has been taking the medication has been advised to see their GP. For more information, please visit the Therapeutic Goods Administration website here.
Main Image by freestocks.org